Enanta Pharmaceuticals
Company raises $20M, begins phase I trial on antibiotic EP-013420
Published in Biotech Law Weekly, October 1st, 2004
The company has also initiated a phase I clinical trial in the United States for its community antibiotic candidate, EP-013420.
Participants in the financing included Shionogi & Co., LTD., and returning investors Techno Venture Management, Oxford Bioscience Partners, BioVentures Investors, and Global Biomedical Partners. The funding will be used to advance EP-013420 in the clinic and to progress the company's discovery-stage anti-infective programs.
First in its class, EP-013420 is a bridged bicyclic ketolide that was designed by Enanta to have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
Source: Biotech Law Weekly (2004-10-01)
More Articles from Biotech Law Weekly
- Adherex Technologies, Inc.
Patent protection strengthened for novel approach to cancer therapy - Applied Biosystems Group
Joint venture in mass spectrometry expanded - Business Update
IntegriGuard wins CMS national contract to oversee Medicare's PDDC-TAP - Cell Therapeutics, Inc.
Biotech company adds general counsel, exercises of over-allotment option - Citizens Against Government Waste
Nonpartisan, nonprofit organization offers ideas on health care and trade - Drug Abuse Treatment
Court to hear arguments on who should determine drug, alcohol treatment - More from this issue of Biotech Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
